Primary results from the phase 3 TOURMALINE-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL) Meeting Abstract
| Authors: | Dispenzieri, A.; Kastritis, E.; Wechalekar, A. D.; Schönland, S. O.; Kim, K.; Sanchorawala, V.; Landau, H. J.; Kwok, F.; Suzuki, K.; Comenzo, R. L.; Berg, D.; Liu, G.; Faller, D. V.; Merlini, G. |
| Abstract Title: | Primary results from the phase 3 TOURMALINE-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL) |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Start Page: | 139 |
| Language: | English |
| ACCESSION: | WOS:000518218500083 |
| DOI: | 10.1182/blood-2019-124409 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 653 -- Source: Wos |
